Abstract:Although the aetiology of Parkinson's disease (PD) and related neurodegenerative disorders is still unknown, recent evidence from human and experimental animal models suggests that a misregulation of iron metabolism, iron-induced oxidative stress and free radical formation are major pathogenic factors. These factors trigger a cascade of deleterious events leading to neuronal death and the ensuing biochemical disturbances of clinical relevance. A review of the available data in PD provides the following evidence in support of this hypothesis: (i) an increase of iron in the brain, which in PD selectively involves neuromelanin in substantia nigra (SN) neurons; (ii) decreased availability of glutathione (GSH) and other antioxidant substances; (iii) increase of lipid peroxidation products and reactive oxygen (O2)species (ROS); and (iv) impaired mitochondrial electron transport mechanisms. Most of these changes appear to be closely related to interactions between iron and neuromelanin, which result in accumulation of iron and a continuous production of cytotoxic species leading to neuronal death. Some of these findings have been reproduced in animal models using 6-hydroxydopamine, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), iron loading and beta-carbolines, although none of them is an accurate model for PD in humans. Although it is not clear whether iron accumulation and oxidative stress are the initial events causing cell death or consequences of the disease process, therapeutic efforts aimed at preventing or at least delaying disease progression by reducing the overload of iron and generation of ROS may be beneficial in PD and related neurodegenerative disorders. Current pharmacotherapy of PD, in addition to symptomatic levodopa treatment, includes 'neuroprotective' strategies with dopamine agonists, monoamine oxidase-B inhibitors (MAO-B), glutamate antagonists, catechol O-methyltransferase inhibitors and other antioxidants or free radical scavengers. In the future, these agents could be used in combination with, or partly replaced by, iron chelators and lazaroids that prevent iron-induced generation of deleterious substances. Although experimental and preclinical data suggest the therapeutic potential of these drugs, their clinical applicability will be a major challenge for future research.

Iron Accumulation Confers Neurotoxicity to a Vulnerable Population of Nigral Neurons: Implications for Parkinson’s Disease

Iron-related Nigral Degeneration Influences Functional Topology Mediated by Striatal Dysfunction in Parkinson's Disease.

The Association of Iron and the Pathologies of Parkinson’s Diseases in MPTP/MPP+-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture

Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Altered Brain Iron Depositions from Aging to Parkinson's Disease and Alzheimer's Disease: A Quantitative Susceptibility Mapping Study

Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study.

Asymmetrical Nigral Iron Accumulation In Parkinson'S Disease With Motor Asymmetry: An Explorative, Longitudinal And Test-Retest Study

Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance

Different Iron Deposition Patterns in Early- and Middle-Late-onset Parkinson's Disease.

An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease

Iron induces the degeneration of nigral dopaminergic neurons in rats

Influence Of Regional Iron On The Motor Impairments Of Parkinson'S Disease: A Quantitative Susceptibility Mapping Study

The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases

Cerebral Iron Deposition in Neurodegeneration

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Iron toxicity, ferroptosis and microbiota in Parkinson's disease: Implications for novel targets

Microglial CR3 promotes neuron ferroptosis via NOX2-mediated iron deposition in rotenone-induced experimental models of Parkinson's disease

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease

Benefits of Iron Chelators in the Treatment of Parkinson’s Disease